Oxford University About the DTU › Home page
› Staff
› Conferences
› Publications
› Slides
› Webcasts
› Contact
› Find us

Software › HOMA Calculator
› Outcomes Model
› Risk Engine

Current Studies › 4-T
› ACE
› EXSCEL
› TECOS
› Translational

Completed Studies › ADOPT
› AFORRD
› DREAM
› EDIT
› FHS
› ISAT
› LDS
  · Home page
  · Protocol
  · Sites
  · Conferences
  · Publications
  · Slides

› UKPDS
› UKPDS~PTM

Intranet Search
Oxford Clinical Trials Logo
CTU Logo
Lipids in Diabetes Study LDS Logo

Home page

The Lipids in Diabetes Study (LDS) was a prospective, randomised, placebo-controlled, clinical outcome trial which commenced recruitment in April 1999. The principal objective of the trial was to determine whether lipid reduction with a statin (cerivastatin) or a fibrate (fenofibrate) could substantially reduce cardiovascular related morbidity and mortality in subjects with type 2 diabetes (non-insulin dependent diabetes). 4191 people with type 2 diabetes but not known coronary heart disease (CHD) and who were not thought to require lipid lowering therapy were randomised to lipid-lowering therapy with cerivastatin (Lipobay) and fenofibrate (Lipantil) in a two-by-two factorial design in thirty UK clinical sites before cerivastatin was withdrawn. Secondary objectives were to assess the effects of the two study drugs on predefined major clinical events, progression of microalbuminuria, changes in digital electrocardiographic parameters and the lipid profile.

  • Principal Investigator: Professor Rury Holman
  • Study Manager: Ms Joanne Keenan

  • ISRCTN number: ISRCTN22144829

News

No recent news articles exist
 

Diabetes Trials Unit

LDS Office, Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ
Tel: +44 (0)1865 857257     Fax: +44 (0)1865 857241     Email: dtu@dtu.ox.ac.uk

Home | Freedom of Information | Privacy Policy | Copyright | Accessibility | OCDEM | NDM | Oxford University